***Bio***

***Dr. David B. Page*** *is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy.*

*He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.*

*He was inspired early in his career at MSKCC when he had the privilege of working alongside mentors Jedd Wolchok and James Allison of the melanoma and immunotherapeutics department, caring for some of the first immune checkpoint therapy patients to be cured of metastatic cancer on the early phase ipilimumab clinical trials. Since then, he has devoted his career to developing immune checkpoint therapies for clinical use in breast cancer, serving as PI for a number of trials, including a phase II study evaluating locoregional cytokine therapy plus pembrolizumab in early stage TNBC, as well as a phase II study evaluating androgen receptor blockade as a mechanism of enhancing immune checkpoint response. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunofluorescence working group.*

*Finally, as a life-long learner, Dr. Page has recently completed a graduate degree in biostatistics, with the aim of applying statistical regression approaches to improve prognostic and predictive performance of biomarkers such as the stromal tumor infiltrating lymphocyte score, and high-throughput assays including RNA sequencing and T-cell receptor sequencing.*